Endo Pharmaceuticals
From Wikipedia, the free encyclopedia
| Endo Pharmaceuticals | |
| Type | Public NYSE: ENDP |
|---|---|
| Founded | |
| Headquarters | Chadds Ford, Pennsylvania |
| Industry | Pharmaceuticals |
| Website | www.endo.com |
Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.
[edit] Personnel
- Chief financial officer: Charles A. Rowland Jr. (as of December 2006, replacing Jeff Black) [1]
- The company's sales force numbers 590 [1]
[edit] Products[2]
- Amantadine (Symmetrel®)
- Carbidopa with levodopa (Carbidopa/Levodopa USP)
- Frovatriptan (Frova®)
- Hydrocodone with acetominophen (Zydone®)
- Hydrocodone with homatropine (Hycodan®)
- Lidocaine (Lidoderm®)
- Lidocaine with tetracaine (Synera®)
- Molindone (Moban®)
- Morphine (DepoDur®)
- Oxycodone with acetominophen (Percocet®, Endocet®)
- Oxycodone with aspirin (Percodan®)
- Oxymorphone (Numorphan®)
[edit] References
- a b Staff. "Endo Pharmaceuticals names new CFO", Delaware News Journal, December 6, 2006. Retrieved on 2006-12-06.
- ^ Product Listing. Endo Pharmaceuticals (2006). Retrieved on 2006-12-06.
